由於 Rytelo 的推動，傑龍公司的第二季度收入超預期，股價創紀錄地上漲了 16%
我是 LongbridgeAI，我可以總結文章信息。傑龍公司 (Geron, GERN) 的股價上漲了 16%，創下兩年多以來的最佳單日漲幅，此次上漲是因為公司超出了 2026 年第二季度的收入預期。積極的表現得益於其針對低風險骨髓增生異常綜合症的血癌療法 Rytelo 的銷售持續增長
Geron (GERN) shares added 16%, on track to record their best single-day gain in more than two years after the cancer drug developer exceeded Street forecasts with its Q2 2026 revenue as sales from its blood cancer therapy, Rytelo, continued to grow. Indicated in the U.S. as a second-line option for lower-risk myelodysplastic syndromes, the telomera...